5 Alpha-reductase inhibitors: What's new?

Current Opinion in Urology

Volumn 13, Issue 1, 2003, Pages 31-37

  Foley, Charlotte L ^a,b   Kirby, Roger S ^a,b  

^a INSTITUTE OF UROLOGY AND NEPHROLOGY   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

5 alpha reductase; Dutasteride; Finasteride; Prostatic hyperplasia; Testosterone

Indexed keywords

ANDROSTANOLONE; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; ISOENZYME; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; TERAZOSIN; TESTOSTERONE;

BLEEDING; BREAST DISEASE; BREAST TENDERNESS; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; EJACULATION DISORDER; ENZYME INHIBITION; GYNECOMASTIA; HEMATURIA; HUMAN; IMPOTENCE; LIBIDO DISORDER; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; SYMPTOM; TREATMENT INDICATION; URINE FLOW RATE; URINE RETENTION;

ADMINISTRATION, ORAL; AGED; AZASTEROIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS; SEVERITY OF ILLNESS INDEX; TESTOSTERONE 5-ALPHA-REDUCTASE; TREATMENT OUTCOME;

EID: 0037241073     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200301000-00006     Document Type: Review

References (48)

1. Borth CS, Beiko DT, Nickel JC. Impact of medical therapy on transurethral resection of the prostate: a decade of change. Urology 2001; 57:1082-1085.
2. Imperato-McGinley J, Shackleton C, Orlic S, Stoner E. C19 and C21 5 beta/ 5 alpha metabolite ratios in subjects treated with the 5 alpha-reductase inhibitor finasteride: comparison of male pseudohermaphrodites with inherited 5 alpha-reductase deficiency. J Olin Endocrinol Metab 1990; 70:777-782.
3. McConnell JD, Wilson JD, George FW, et al. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992; 74:505-508.
4. Norman RW, Coakes KE, Wright AS, Rittmaster RS. Androgen metabolism in men receiving finasteride before prostatectomy. J Urol 1993; 150:1736-1739.
5. Russell DW, Wilson JD. Steroid 5 alpha-reductase: two genes/two enzymes. Annu Rev Biochem 1994; 63:25-61.
6. Thigpen AE, Silver RI, Guileyardo JM, et al. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest 1993; 92:903-910.
7. Aumuller G, Eicheler W, Renneberg H, et al. Immunocytochemical evidence for differential subcellular localization of 5 alpha-reductase isoenzymes in human tissues. Acta Anat (Basel) 1996; 156:241-252.
8. Rittmaster RS, Norman RW, Thomas LN, Rowden G. Evidence for atrophy and apoptosis in the prostates of men given finasteride. J Olin Endocrinol Metab 1996; 81:814-819.
9. Marks LS, Partin AW, Gormley GJ, et al. Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia. J Urol 1997; 157:2171-2178.
10. Steers WD. 5 Alpha-reductases activity in the prostate. Urology 2001; 58 (suppl. 6a):17-24. A useful review covering the role of 5 alpha-reductase enzyme in fertility and development as well as BPH.
11. Geller J. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen. J Clin Endocrinol Metab 1990; 71:1552-1555.
12. Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5 alpha-reductase inhibition in human benign prostatic hyperplasia. World J Urol 2002; 19:413-425. This excellent and exhaustive review covers the rope of 5 alpha-reductase and the effects of inhibitors in a logical order, from the molecular biological effects of androgens to the pharmacology of 5 alpha-reductase inhibitors and their clinical effects.
13. Fukuta Y, Fukuda Y, Higashino R, et al. Z-350, a novel compound with alpha 1-adrenoceptor antagonistic and steroid 5 alpha-reductase inhibitory actions: pharmacological properties in vivo. J Pharmcol Exp Thor 1999; 290:1013-1018.
14. Fukuda Y, Fukuta Y, Higashino R, et al. Hormonal effects of Z-350, possessing steroid 5 alpha-reductase inhibitory and alpha1-adrenoceptor antagonistic actions, in the rat. Jpn J Pharmacol 2001; 86:323-328.
15. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992; 327:1185-1191.
16. Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993; 22:291-299.
17. Nickel JC, Fradet Y, Boake RC, et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. Can Med Assoc J 1996; 155:1251-1259.
18. Andersen JT, Ekman P, Wolf H, et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group. Urology 1995; 46:631-637.
19. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998; 338:557-563.
20. Andersen JT, Nickel JC, Marshall VR, et al. Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology 1997; 49:839-845.
21. Marberger MJ. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group. Urology 1998; 51:677-686.
22. Andriole G, Guess HA, Epstein JI, et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomised, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. Urology 1998; 52:195-201.
23. Boyle P, Gould AL, Roehrborn CO. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48:398-405.
24. Roehrborn CG, Andriole G, Nickel C, et al. Effect of dutasteride, a novel dual 5-alpha-reductase inhibitor, on BPH related signs and symptoms [Abstract 1043]. J Urol 2002; 167 (4, Suppl.): 265.
25. Roehrborn CG, Andriole G, Nickel C, Boyle P. Effect of the dual 5-alpha-reductase inhibitor dutasteride on endocrine parameters [Abstract 1049]. J Urol 2002; 167 (4, Suppl.): 266-267.
26. Andriole G, Roehrborn CG, Nickel C, Boyle P. Effect of the dual 5-alpha-reductase inhibitor, dutasteride, on serum total PSA, free PSA and the ratio of F/T PSA [Abstract 844]. J Urol 2002; 167 (4, Suppl.): 209-210.
27. Boyle P, Siami P, Wachs BH, et al. Effect of dutasteride on the risk of acute urinary retention and the need for surgical treatment [Abstract 1479]. J Urol 2002; 167 (4, Suppl.): 372.
28. Roehrborn CG, Ramsdell J, Siami P, et al. Prostate volume at baseline predicts the margin of therapeutic response with the 5-alpha-reductase inhibitor, dutasteride [Abstract 1483]. J Urol 2002; 167 (4, Suppl.): 373.
29. Roehrborn CG, Boyle PJ, Nickel C, Hoefner K, Andriole G on behalf of the ARIA3001, ARIA3002 and ARIA3003 study investigators. Efficacy and safety of a dual inhibitor or 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60:434-441. The formal publication of the 3 clinical trials establishing the clinical efficacy and biochemical effects of dutasteride, the newest and second available 5 alpha reductase inhibitor.
30. Roehrborn CG, McConnell JD, Lieber M, et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. The PLESS Study Group. Urology 1999; 53:473-480.
31. Roehrborn CG. Is there a place for combination medical therapy? Curr Opin Urol 2001; 11:17-25.
32. Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996; 335:533-539.
33. Roehrborn C, for the PREDICT Steering Committee and the PREDICT investigators. A double-blind comparison of doxazosin and finasteride in symptomatic benign prostatic hyperplasia: a multinational European trial [Abstract]. Eur Urol 2000; 37 (Suppl. 2):118.
34. Roehrborn C, for the PREDICT Study Group. Categorical flow rate changes in men with LUTS and BPH treated with doxazosin, finasteride or combination versus placebo [Abstract]. J Urol 2000; 163:309.
35. Lepor H, Williford WO, Barry MJ, et al. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. J Urol 1998; 160:1358-1367.
36. McConnell JD, for the MTOPS Steering Committee. The long term effects of medical therapy on the progression of BPH: results from the MTOPS trial [Abstract 1042]. J Urol 2002; 167 (4, Suppl.): 265.
37. Baldwin KC, Ginsberg PC, Roehrborn CG, Harkaway RC. Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology 2001; 58:203-209. An interesting study on the impact of alpha adrenergic antagonist withdrawal from combination therapy, a pragmatic third way in addition to monotherapy and combination therapy. Whereas there is no placebo group and only a brief follow-up, this strategy appears to be tolerated in the short term by a majority of patients with prostates over 40 mg.
38. Puchner PJ, Miller MI. The effects of finasteride on hematuria associated with benign prostatic hyperplasia: a preliminary report. J Urol 1995; 154:1779-1782.
39. Delakas D, Llanos E, Karyotis I, Cranidis A. Finasteride: a long-term follow-up in the treatment of recurrent hematuria associated with benign prostatic hyperplasia. Urol Int 2001; 67:69-72.
40. Kearney MC, Bingham JB, Bergland R, et al. Clinical predictors in the use of finasteride for control of gross haematuria due to benign prostatic hyperplasia. J Urol 2002; 167:2489-2491.
41. Rosenthal B, Ginsberg PC, Harkaway RC. The relationship between prostate size and the efficacy of finasteride in the treatment of BPH related haematuria [Abstract 1498]. J Urol 2002; 167 (4, Suppl.):376.
42. Hochberg DA, Basillote JB, Armenakas NA, et al. Decreased suburethral prostatic microvessel density in finasteride treated prostates: a possible mechanism for reduced bleeding in benign prostatic hyperplasia. J Urol 2002; 167:1731-1733.
43. Marshall S, Narayan P. Treatment of prostatic bleeding: suppression of angiogenesis by androgen deprivation. J Urol 1993; 149:1553-1554.
44. Levine AC, Liu XH, Greenberg PD, et al. Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts. Endocrinology 1998; 139:4672-4678.
45. Hagerty JA, Ginsberg PC, Harmon JD, Harkaway RC. Pretreatment with finasteride decreases perioperative bleeding associated with transurethral resection of the prostate. Urology 2000; 55:684-689.
46. Sandfeldt L, Bailey DM, Hahn RG. Blood loss during transurethral resection of the prostate after 3 months of treatment with finasteride. Urology 2001; 58:972-976.
47. Feigl P, Blumenstein B, Thompson I, et al. Design of the Prostate Cancer Prevention Trial (PCPT). Control Clin Trials 1995; 16:150-163.
48. Coltman CA Jr, Thompson IM Jr, Feigl P. Prostate Cancer Prevention Trial (PCPT) update. Eur Urol 1999; 35:544-547.